Trial Profile
Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Telomeric 22q13 Monosomy Syndrome
- Focus Therapeutic Use
- 15 Oct 2020 Status changed from recruiting to completed.
- 12 Jun 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 12 Jun 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.